MX371090B - Composicion farmaceutica que contiene derivado de hidantoina. - Google Patents

Composicion farmaceutica que contiene derivado de hidantoina.

Info

Publication number
MX371090B
MX371090B MX2016013684A MX2016013684A MX371090B MX 371090 B MX371090 B MX 371090B MX 2016013684 A MX2016013684 A MX 2016013684A MX 2016013684 A MX2016013684 A MX 2016013684A MX 371090 B MX371090 B MX 371090B
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
containing pharmaceutical
hydantoin derivative
formula
hydantoin
Prior art date
Application number
MX2016013684A
Other languages
English (en)
Other versions
MX2016013684A (es
Inventor
Kitamura Hidetomo
Tamura Tatsuya
Noda Horoshi
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2016013684A publication Critical patent/MX2016013684A/es
Publication of MX371090B publication Critical patent/MX371090B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición farmacéutica para inducir una acción de absorción del hueso y/o cartílago, que incluye como un componente eficaz de la misma un compuesto indicado por la fórmula general (1) o una sal farmacológicamente aceptable del mismo (en la fórmula, R1, R2, R3, y R4 son como se definen en las Reivindicaciones).
MX2016013684A 2014-06-09 2014-06-09 Composicion farmaceutica que contiene derivado de hidantoina. MX371090B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2014/065262 WO2015189901A1 (ja) 2014-06-09 2014-06-09 ヒダントイン誘導体含有医薬組成物

Publications (2)

Publication Number Publication Date
MX2016013684A MX2016013684A (es) 2017-01-20
MX371090B true MX371090B (es) 2020-01-16

Family

ID=54833033

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013684A MX371090B (es) 2014-06-09 2014-06-09 Composicion farmaceutica que contiene derivado de hidantoina.

Country Status (10)

Country Link
US (1) US9993462B2 (es)
EP (1) EP3153166B1 (es)
KR (2) KR102266021B1 (es)
CN (2) CN106572994B (es)
AU (1) AU2014397042B2 (es)
BR (1) BR112016003511B8 (es)
CA (1) CA2949023C (es)
MX (1) MX371090B (es)
RU (1) RU2701168C2 (es)
WO (2) WO2015189901A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104854106B (zh) * 2012-12-10 2017-07-04 中外制药株式会社 乙内酰脲衍生物
CA3107665A1 (en) * 2018-07-30 2020-02-06 Chugai Seiyaku Kabushiki Kaisha Solid dispersion of hydantoin derivative

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1135470A (ja) 1997-07-23 1999-02-09 Teijin Ltd ビタミンｄ３誘導体を含有する副甲状腺ホルモン産生促進剤
BR9916005A (pt) 1998-12-11 2001-09-04 Hoffmann La Roche Derivados de hidrazina cìclicos como inibidores do tnf-alfa
WO2002017911A1 (fr) 2000-08-30 2002-03-07 Teijin Limited Inhibiteurs de la production de parathormone contenant des derives de vitamine d3
CA2425283A1 (en) 2000-10-26 2002-05-02 Pfizer Products Inc. Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
AR038658A1 (es) 2001-06-15 2005-01-26 Novartis Ag Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento
WO2005077959A1 (en) 2004-02-11 2005-08-25 Smithkline Beecham Corporation Pth agonists
WO2005077918A1 (en) 2004-02-11 2005-08-25 Smithkline Beecham Corporation Pth agonists
JP2008515895A (ja) 2004-10-07 2008-05-15 メルク エンド カムパニー インコーポレーテッド Ｃｇｒｐ受容体拮抗薬
WO2007135417A1 (en) 2006-05-19 2007-11-29 James Black Foundation Benzotriazepinone derivatives
EP2035420A2 (en) 2006-06-20 2009-03-18 Wyeth a Corporation of the State of Delaware Kv1.5 potassium channel inhibitors
TW200831080A (en) * 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
MX2009013115A (es) 2007-06-07 2010-01-15 Hoffmann La Roche Derivados de prolinamida como antagonistas de nk3.
KR101578235B1 (ko) 2007-12-10 2015-12-16 노파르티스 아게 유기 화합물
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
WO2010045229A2 (en) 2008-10-13 2010-04-22 University Of Rochester Protecting and repairing cartilage and musculoskeletal soft tissues
PL2433940T3 (pl) 2009-04-28 2015-03-31 Chugai Pharmaceutical Co Ltd Pochodna spiroimidazolonu
CN104854106B (zh) * 2012-12-10 2017-07-04 中外制药株式会社 乙内酰脲衍生物

Also Published As

Publication number Publication date
CN106572994A (zh) 2017-04-19
BR112016003511A2 (es) 2017-08-01
EP3153166B1 (en) 2022-08-03
RU2016113896A (ru) 2018-07-18
EP3153166A4 (en) 2018-01-17
RU2701168C2 (ru) 2019-09-25
RU2016113896A3 (es) 2018-07-18
AU2014397042A1 (en) 2016-02-11
AU2014397042B2 (en) 2020-04-09
KR102382331B1 (ko) 2022-04-01
KR20170010354A (ko) 2017-01-31
US20170112812A1 (en) 2017-04-27
CA2949023C (en) 2021-10-12
BR112016003511A8 (pt) 2018-01-30
CA2949023A1 (en) 2015-12-17
KR20170010439A (ko) 2017-01-31
CN106535892B (zh) 2020-09-18
BR112016003511B1 (pt) 2022-11-08
BR112016003511B8 (pt) 2023-10-03
MX2016013684A (es) 2017-01-20
CN106572994B (zh) 2020-09-18
WO2015189901A1 (ja) 2015-12-17
US9993462B2 (en) 2018-06-12
EP3153166A1 (en) 2017-04-12
WO2015190451A1 (ja) 2015-12-17
CN106535892A (zh) 2017-03-22
KR102266021B1 (ko) 2021-06-16

Similar Documents

Publication Publication Date Title
PH12016501813A1 (en) 1,3-benzodioxole derivative
MX2018007022A (es) Metodos para tratar la enfermedad de huntington.
MA39986A (fr) Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MX2018009459A (es) Derivado de sulfonamida y composicion farmaceutica que contiene el mismo.
MA39956A (fr) Analogues du benzomorphane et leur utilisation
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
PH12017501280B1 (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
MX2018001517A (es) Derivados sustituidos de guanidina.
GEP201706760B (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
MY162886A (en) Novel tetrahydropyridopyrimidine compound or salt thereof
PH12016500461A1 (en) Polyethylene glycol-containing composition
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
WO2018039077A8 (en) Therapeutic compounds
PH12015501146A1 (en) Hydantoin derivative
GEP20186893B (en) Pyrazines modulators of gpr6
MX371090B (es) Composicion farmaceutica que contiene derivado de hidantoina.
MA39877A (fr) Formes solides d'un composé pharmaceutiquement actif
PH12017501134A1 (en) Fumagillol derivatives
EA201690908A1 (ru) Пиразолопиримидиновые соединения
MX2019007786A (es) Compuestos sustituidos de guanidina.

Legal Events

Date Code Title Description
FG Grant or registration